leadf
logo-loader
viewCanntab Therapeutics Ltd

Canntab Therapeutics received purchase order from Australia while also taking part in research study

Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive Vancouver with news the company has announced the launch of its suite of hard pill cannabinoid formulations in Australia with its partner CANN Global Ltd.

Goldstein takes Proactive through the first deal of the company overseas and he also shares news Canntab will be taking part in Australia's largest observational study ever undertaken for medical cannabis.

Quick facts: Canntab Therapeutics Ltd

Price: 0.67 CAD

CSE:PILL
Market: CSE
Market Cap: $22.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Canntab Therapeutics achieves major milestone receiving first U.S. patent...

Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CEO Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has secured protection for their intellectual property receiving a U.S. patent for “Modified Release Multi-Layer Tablet Cannabinoid Formulations.” Latowsky...

on 21/9/20

2 min read